Dynatrace Inc. Common Stock vs DexCom, Inc. — how do they compare? Dynatrace Inc. Common Stock trades at $61.22 (market cap $17.29B), while DexCom, Inc. trades at $84.46 (market cap $31.81B). The key difference: DexCom, Inc. is the larger of the two by market cap, and Dynatrace Inc. Common Stock is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dynatrace Inc. Common Stock for 0 Days and DexCom, Inc. for 62 Days on average.
| DT | DXCM | |
|---|---|---|
Market Cap | $17.29B | $31.81B |
Volume | 5,001,840 | 2,861,821 |
Sector | Technology | Health |
52-Week High | $61.12 | $92.34 |
52-Week Low | $32.36 | $54.84 |
Typical Hold Time | 0 Days | 62 Days |
Enterprise Value | $16.34B | $31.26B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
DexCom (DXCM) trades at $84.41, showing modest daily gains of 1.22% amid a bearish technical outlook. The company demonstrates strong fundamental performance with consistent earnings beats, including Q2 2026 EPS of $0.70 exceeding expectations of $0.611. Revenue growth remains robust, climbing from $2.9B in 2022 to $4.7B in 2025, while net income margins improved to 17.93%. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
Wall Street maintains a bullish stance with 81% buy ratings and a $95.07 consensus price target, representing 13% upside potential. Key risks include competitive pressures in CGM markets and reimbursement challenges. The company's strong cash flow generation and expanding market opportunity in diabetes technology support long-term growth prospects despite current technical weakness.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Dynatrace provides an observability, security, and automation platform for cloud and IT environments. Its platform integrates data such as logs, metrics, and traces to help organizations monitor digital systems.
Read more on DT →Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →